Equity Overview
Price & Market Data
Price: $37.68
Daily Change: -$0.57 / 1.51%
Daily Range: $37.50 - $40.40
Market Cap: $152,662,224
Daily Volume: 33,214
Performance Metrics
1 Week: -1.65%
1 Month: 6.80%
3 Months: -8.69%
6 Months: 72.66%
1 Year: 146.9%
YTD: -2.46%
Company Details
Employees: 26
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.